来源/采访对象提供10月17日，复旦大学附属华山医院毛颖教授、花玮教授、迟喻丹研究员团队在国际肿瘤学权威期刊Cancer Cell在线发表了题为Overcoming tyrosine kinase inhibitor resistance in ...

该研究利用单细胞测序技术，对 肺癌 脑转移样本进行了深入分析，揭示了TKI靶向药物奥希替尼在治疗过程中的耐药机制。奥希替尼不仅能够显著提升T细胞在肿瘤中的浸润度，还促使 免疫 检查点CTLA4的表达上调。这种机制的出现最终导致了 肿瘤细胞 ...

Intensive chemotherapy combined with second- or third-generation tyrosine kinase inhibitors improves survival in patients ...

奥希替尼是一种三代表皮生长因子（Epidermal Growth Factor Receptor, EGFR）酪氨酸激酶抑制剂（Tyrosine Kinase Inhibitor, TKI），目前是携带 EGFR ...

为了提高肿瘤的治疗效果，抗肿瘤药物常采用联合方案进行治疗，一般包括两种或两种以上药物，其主要目的是为了让不同的药物作用于肿瘤细胞的不同细胞周期或靶点，从而增加治疗效果。合理正确地进行药物输注可以起到协同效应，不仅可以提高疗效，还可以减少或避免毒性，消 ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

This article will describe the development of erlotinib, an EGFR tyrosine kinase inhibitor (EGFR-TKI), focusing on the clinical data reported in the treatment of NSCLC. Clorinda Schettino ...

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic ...

The ASC4FIRST trial explores asciminib for chronic myeloid leukaemia, but experts question its design and outcomes, ...

上述研究结果证实了TACE联合靶向免疫治疗的协同增效作用，并形成了完整的证据链，尤其对BCLC指南中晚期肝癌的治疗策略提出了挑战。我国2024年版CNLC指南已将Ⅲa期的治疗手段更新为TACE/TACE+，这一更新对于晚期肝癌的治疗具有里程碑式的意义 ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...